FDA Vaccine Chief Dr. Vinay Prasad Departs Agency for Second Time Amid String of Controversies

The Food and Drug Administration's embattled vaccine and biotech chief, Dr. Vinay Prasad, is once again leaving the agency — marking the second time in less than a year that he has departed following a series of high-profile controversies involving vaccine reviews, gene therapies, and specialty drugs for rare diseases.

FDA Commissioner Marty Makary announced the departure in an email to FDA staff late Friday, confirming that Prasad would leave at the end of April and return to his academic position at the University of California, San Francisco. Makary offered no further public explanation for the timing of the announcement.

This is not the first time Prasad has found himself at the center of institutional turbulence. In July, he was briefly forced out of his role after drawing sharp criticism from biotech executives, patient advocacy groups, and conservative allies of President Donald Trump. He was reinstated less than two weeks later, reportedly with the support of Health Secretary Robert F. Kennedy Jr. and Commissioner Makary.

Prasad's latest departure comes after a rapid succession of contentious decisions that drew fierce criticism from pharmaceutical executives, investors, and members of Congress alike. Among the most notable incidents, Prasad initially refused to allow the FDA to review a highly anticipated mRNA-based flu vaccine developed by Moderna — an unusually aggressive rejection that prompted the drugmaker to publicly challenge the decision and vow a formal appeal. Just one week after the rejection became public, the FDA reversed course, agreeing to accept the application pending an additional study from Moderna.

Further controversy erupted in the days that followed, when the FDA engaged in a highly unusual public dispute with UniQure, a small biopharmaceutical company developing an experimental gene therapy for Huntington's Disease — a fatal neurological condition affecting approximately 40,000 Americans. UniQure alleged that the FDA had demanded a new clinical trial requiring sham brain surgery on some participants, a request the company characterized as ethically problematic and contradictory to prior regulatory guidance. In an equally unprecedented move, senior FDA officials held a press conference to defend the agency's position, publicly describing UniQure's original study as "stone cold negative" and characterizing the therapy as a "failed product" — language rarely used by regulators discussing drugs still under active agency review.

Since joining the FDA in May of last year, Prasad's regulatory tenure has been defined by paradox. On multiple occasions, he joined Makary in announcing initiatives intended to streamline and accelerate FDA drug reviews. Yet simultaneously, he imposed new warning requirements and additional study mandates on numerous biotech products, including COVID-19 vaccines — therapies that have long been scrutinized by Kennedy, a prominent vaccine skeptic prior to joining the Trump administration.

More than half a dozen drugmakers developing treatments for rare or difficult-to-treat diseases received rejection letters or demands for supplemental studies under Prasad's oversight, potentially adding years and tens of millions of dollars to their development timelines. His departure leaves significant uncertainty about the FDA's regulatory direction at a critical moment for the agency's credibility and its relationships with the broader pharmaceutical industry.